LOLukas Minus Orre

Lukas Minus Orre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lukas Minus Orre has a total of 246 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting the FBXL12–FANCD2 Pathway Disrupts Replication Stress Tolerance in MYCN-Driven Neuroblastoma

    by Jinjiang Chou, Alena Malyukova, Alessandro Simone Bordonaro, Krzysztof Dygon, Lena Litzenburger, Ervelina Dalani, Jiayu Xiao, Conny Tümmler, Georgios Mermelekas, Janith Seniveratne, et al.

    MYCN amplification drives replication stress in high-risk neuroblastoma, yet how MYCN-amplified tumour cells tolerate this stress to sustain proliferation remains poorly understood. Here we show that FBXL12, an SCF ubiquitin ligase substrate receptor that targets the Fanconi anaemia protein FANCD2 for degradation at replication forks, as well as the broader Fanconi anaemia and replication stress transcriptional program are elevated in high-risk and MYCN-amplified neuroblastoma. High FBXL12 expression independently predicts poor survival across neuroblastoma patient cohorts. FBXL12 loss stabilizes FANCD2 on chromatin, elevates ATR-dependent replication stress signalling and DNA damage during S phase, and impairs proliferation of MYCN-amplified neuroblastoma cells in vitro and in vivo. Mechanistically, MYCN directly engages the FBXL12-FANCD2 complex and antagonises FBXL12-mediated degradation of FANCD2 at replication forks, revealing that the oncogenic driver of replication stress also actively preserves the chromatin-bound FANCD2 pool required to tolerate it. Beyond S phase, FBXL12 loss disrupts FANCD2-dependent mitotic DNA synthesis and transmits unresolved replication intermediates into daughter cells. FBXL12-deficient cells consequently show transcriptional activation of MYC target gene, ATR, and mTOR signalling programs, and this pathway-concordant state confers differential sensitivity to ATR, and mTOR-targeting compounds, nominating candidate therapeutic strategies for this disease subset. Together, these findings define a MYCN-FBXL12-FANCD2 axis as a clinically relevant vulnerability in high-risk neuroblastoma. HIGHLIGHTS: FBXL12 is upregulated in high-risk neuroblastoma and predicts poor survival FBXL12 loss traps FANCD2 on chromatin and drives S-phase DNA damage MYCN antagonises FBXL12-mediated degradation of FANCD2 at replication forks FBXL12 loss impairs mitotic DNA synthesis and damages daughter cells FBXL12-deficient cells show ATR/mTOR activation and drug sensitivity

  • Open Access

    Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides

    by Olena Berkovska, Igor Schliemann, Georgios Mermelekas, Nazlı Ezgi Özkan, Mahnaz Nikpour, Vilde Drageset Haakensen, Åslaug Helland, Janne Lehtiö, Lukas M. Orre

    Clinical proteomics has the potential to add a valuable data layer to genomic and histopathological analyses in precision oncology, but its application to limited clinical material remains challenging. Here, we demonstrate that state-of-the-art mass spectrometry-based proteomics enables in-depth proteomic profiling of formalin-fixed paraffin-embedded (FFPE) clinical samples, including small diagnostic biopsies and single tissue sections mounted on glass slides. Despite minimal input material, single-slide analyses of clinical lung tumor specimens yielded biologically and clinically informative data, supporting detection of actionable proteins, immune-related signatures, and multivariate biomarkers. These results establish the feasibility of proteomics for retrospective FFPE studies and routine clinical practice, expanding opportunities for biomarker discovery and precision medicine from scarce tissue material.


  • Differential protein expression analysis of quantitative mass spectrometry data using DEqMS

    by Yafeng Zhu, Olena Berkovska, Lingshuo Wang, Mei Yang, Henrik J. Johansson, Georgios Mermelekas, Mahshid Zarrineh, Dong Yin, Lukas M. Orre, Janne Lehtiö

    DEqMS is an R package-based statistical tool for differential protein expression analysis in quantitative mass spectrometry-based proteomics. It implements a robust Bayesian method for accurate variance estimation that accounts for the number of mass spectrometry features used for protein quantification (number of peptide precursors or peptide spectrum matches). Originally validated for data-dependent acquisition proteomics, DEqMS now extends to data-independent acquisition workflows, as demonstrated using both spike-in and real-world datasets. Given a peptide- or protein-level quantification table with mass spectrometry feature count as inputs, DEqMS outputs a protein- or gene-level results table containing fold changes and multiple statistics (t-values, P value, among others) adjusted according to mass spectrometry feature count. Here we detail the use of the DEqMS R package. This updated workflow broadens DEqMS's applicability, enabling researchers with basic R programming knowledge to identify proteins with significantly altered abundance between sample groups across diverse quantitative proteomics datasets. DEqMS is available to install at https://bioconductor.org/packages/DEqMS/ .


  • Open Access

    Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides

    by Olena Berkovska, Igor Schliemann, Georgios Mermelekas, Nazlı Ezgi Özkan, Mahnaz Nikpour, Vilde Drageset Haakensen, Åslaug Helland, Janne Lehtiö, Lukas M. Orre

    Clinical proteomics has the potential to add a valuable data layer to genomic and histopathological analyses in precision oncology, but its application to limited clinical material remains challenging. Here, we demonstrate that state-of-the-art mass spectrometry-based proteomics enables in-depth proteomic profiling of formalin-fixed paraffin-embedded (FFPE), including small biopsies and single tissue sections mounted on glass slides. Despite minimal input material, single-slide analyses of clinical lung tumor specimens yielded biologically and clinically informative data, supporting detection of actionable proteins, immune-related signatures, and multivariate biomarkers. These results establish the feasibility of proteomics for retrospective FFPE studies and routine clinical practice, expanding opportunities for biomarker discovery and precision medicine from scarce tissue material.


  • Open Access

    Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer

    by Yanbo Pan, Olena Berkovska, Soumitra Marathe, Georgios Mermelekas, Greta Gudoityte, Amare D. Wolide, Taner Arslan, Brinton Seashore-Ludlow, Janne Lehtiö, Lukas M. Orre


  • Open Access

    The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia

    by Daniel Hägerstrand, Blaž Oder, Diego Cortese, Ying Qu, Amrei Binzer-Panchal, Cecilia Österholm, Teresa Del Peso Santos, Leily Rabbani, Hassan Foroughi Asl, Aron Skaftason, et al.

    SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1MUT and 17 SF3B1WT subset #2 cases and identified 80 significant alternative splicing events (ASEs). Notable ASEs concerned exon inclusion in the non-canonical BAF (ncBAF) chromatin remodeling complex subunit, BRD9, and splice variants in eight additional ncBAF complex interactors. Long-read RNA-sequencing confirmed the presence of splice variants, and extended analysis of 139 CLL cases corroborated their association with SF3B1 mutations. Overexpression of SF3B1K700E induced exon inclusion in BRD9, resulting in a novel splice isoform with an alternative C-terminus. Protein interactome analysis of the BRD9 splice isoform revealed augmented ncBAF complex interaction, while exhibiting decreased binding of auxiliary proteins, including SPEN, BRCA2, and CHD9. Additionally, integrative multi-omics analysis identified a ncBAF complex-bound gene quartet on chromosome 1 with higher expression levels and more accessible chromatin in SF3B1MUT CLL. Finally, Cancer Dependency Map analysis and BRD9 inhibition displayed BRD9 dependency and sensitivity in cell lines and primary CLL cells. In conclusion, spliceosome dysregulation caused by SF3B1 mutations leads to multiple ASEs and an altered ncBAF complex interactome, highlighting a novel pathobiological mechanism in SF3B1MUT CLL.


  • Open Access

    Delineating functional and molecular impact of ex vivo sample handling in precision medicine

    by Nona Struyf, Albin Österroos, Mattias Vesterlund, Cornelia Arnroth, Tojo James, Stephanie Sunandar, Georgios Mermelekas, Anna Bohlin, Kerstin Hamberg Levedahl, Sofia Bengtzén, et al.

    Consistent handling of samples is crucial for achieving reproducible molecular and functional testing results in translational research. Here, we used 229 acute myeloid leukemia (AML) patient samples to assess the impact of sample handling on high-throughput functional drug testing, mass spectrometry-based proteomics, and flow cytometry. Our data revealed novel and previously described changes in cell phenotype and drug response dependent on sample biobanking. Specifically, myeloid cells with a CD117 (c-KIT) positive phenotype decreased after biobanking, potentially distorting cell population representations and affecting drugs targeting these cells. Additionally, highly granular AML cell numbers decreased after freezing. Secondly, protein expression levels, as well as sensitivity to drugs targeting cell proliferation, metabolism, tyrosine kinases (e.g., JAK, KIT, FLT3), and BH3 mimetics were notably affected by biobanking. Moreover, drug response profiles of paired fresh and frozen samples showed that freezing samples can lead to systematic errors in drug sensitivity scores. While a high correlation between fresh and frozen for the entire drug library was observed, freezing cells had a considerable impact at an individual level, which could influence outcomes in translational studies. Our study highlights conditions where standardization is needed to improve reproducibility, and where validation of data generated from biobanked cohorts may be particularly important.


  • SubCellBarCode: integrated workflow for robust spatial proteomics by mass spectrometry

    by Taner Arslan, Yanbo Pan, Georgios Mermelekas, Mattias Vesterlund, Lukas M. Orre, Janne Lehtiö

    The molecular functions of a protein are defined by its inherent properties in relation to its environment and interaction network. Within a cell, this environment and network are defined by the subcellular location of the protein. Consequently, it is crucial to know the localization of a protein to fully understand its functions. Recently, we have developed a mass spectrometry– (MS) and bioinformatics-based pipeline to generate a proteome-wide resource for protein subcellular localization across multiple human cancer cell lines (www.subcellbarcode.org). Here, we present a detailed wet-lab protocol spanning from subcellular fractionation to MS-sample preparation and analysis. A key feature of this protocol is that it includes all generated cell fractions without discarding any material during the fractionation process. We also describe the subsequent quantitative MS-data analysis, machine learning–based classification, differential localization analysis and visualization of the output. For broad applicability, we evaluated the pipeline by using MS data generated by two different peptide pre-fractionation approaches, namely high-resolution isoelectric focusing and high-pH reverse-phase fractionation, as well as direct analysis without pre-fractionation by using long-gradient liquid chromatography-MS. Moreover, an R package covering the dry-lab part of the method was developed and made available through Bioconductor. The method is straightforward and robust, and the entire protocol, from cell harvest to classification output, can be performed within 1–2 weeks. The protocol enables accurate classification of proteins to 15 compartments and 4 neighborhoods, visualization of the output data and differential localization analysis including treatment-induced protein relocalization, condition-dependent localization or cell type–specific localization. The SubCellBarCode package is freely available at https://bioconductor.org/packages/devel/bioc/html/SubCellBarCode.html.


  • Top Cited Papers
    Open Access

    Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin

    by Rosanne E. Veerman, Loes Teeuwen, Paulo Czarnewski, Gözde Güclüler Akpinar, AnnSofi Sandberg, Xiaofang Cao, Maria Pernemalm, Lukas M. Orre, Susanne Gabrielsson, Maria Eldh

    Extracellular vesicles (EVs) are increasingly tested as therapeutic vehicles and biomarkers, but still EV subtypes are not fully characterised. To isolate EVs with few co‐isolated entities, a combination of methods is needed. However, this is time‐consuming and requires large sample volumes, often not feasible in most clinical studies or in studies where small sample volumes are available. Therefore, we compared EVs rendered by five commonly used methods based on different principles from conditioned cell medium and 250 μl or 3 ml plasma, that is, precipitation (ExoQuick ULTRA), membrane affinity (exoEasy Maxi Kit), size‐exclusion chromatography (qEVoriginal), iodixanol gradient (OptiPrep), and phosphatidylserine affinity (MagCapture). EVs were characterised by electron microscopy, Nanoparticle Tracking Analysis, Bioanalyzer, flow cytometry, and LC‐MS/MS. The different methods yielded samples of different morphology, particle size, and proteomic profile. For the conditioned medium, Izon 35 isolated the highest number of EV proteins followed by exoEasy, which also isolated fewer non‐EV proteins. For the plasma samples, exoEasy isolated a high number of EV proteins and few non‐EV proteins, while Izon 70 isolated the most EV proteins. We conclude that no method is perfect for all studies, rather, different methods are suited depending on sample type and interest in EV subtype, in addition to sample volume and budget.


  • Open Access

    Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC

    by Yan Zhou Tran, Rezan Minozada, Xiaofang Cao, Henrik J. Johansson, Rui M. Branca, Brinton Seashore-Ludlow, Lukas M. Orre